No Data
No Data
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
Nektar Therapeutics Is Maintained at Hold by Jefferies
Nektar Therapeutics Is Maintained at Hold by Jefferies
Express News | Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Nektar Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 13.64% Jefferies $0.5 → $1 Maintains Hold 11/20/2023 — JP Morgan Reinstates → Underweight 11/0
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Nektar Therapeutics (NKTR) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpe
No Data